ARTICLE | Clinical News
ALXN1210: Preliminary Phase I/II data
June 20, 2016 7:00 AM UTC
Preliminary data from 13 patients with PNH in a 24-week, open-label, dose-escalation, international Phase I/II trial showed that once-monthly ALXN1210 led to a mean reduction in LDH levels of 85.4% at...